New treatment milestone offers fresh hope for Australians living with CIDP

This is a preview of subscriber content

Subscribe now to continue reading.

“As the first therapy with a novel mechanism of action to be approved for CIDP patients in more than 30 years, this approval is an extremely important step towards addressing the unmet needs of patients with this debilitating condition and further signals argenx’s commitment to bring innovative therapeutic options to Australian patients,” said Kathryn Evans, Australia General Manager for argenx. …

Subscribe now to continue reading.

New treatment milestone offers fresh hope for Australians living with CIDP

This is a preview of subscriber content

Latest Video

Most Read

Budget confirms what we already knew and what we had guessed. What a surprise

Frustrated minister encourages an early negotiation of new agreements

There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this

Budget could back HTA groundwork while significant reform waits

Updated forecast highlights the real risk of relying on these numbers

New Stories

Frustrated minister encourages an early negotiation of new agreements

Long-term study finds continuing Mounjaro helps maintain weight loss

GBMA welcomes Budget pathway to increasing biosimilar uptake

There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this

Disappointment for diabetes advocates in response to Government budget silence

Updated forecast highlights the real risk of relying on these numbers

Baxter and MTAA launch Australian Healthcare Manufacturing Leaders Network

Sign In

New treatment milestone offers fresh hope for Australians living with CIDP

This is a preview of subscriber content

Latest Video

Most Read

Budget confirms what we already knew and what we had guessed. What a surprise

Frustrated minister encourages an early negotiation of new agreements

There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this

Budget could back HTA groundwork while significant reform waits

Updated forecast highlights the real risk of relying on these numbers

Follow Us

New Stories

Frustrated minister encourages an early negotiation of new agreements

Long-term study finds continuing Mounjaro helps maintain weight loss

GBMA welcomes Budget pathway to increasing biosimilar uptake

There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this

Disappointment for diabetes advocates in response to Government budget silence

Updated forecast highlights the real risk of relying on these numbers

Baxter and MTAA launch Australian Healthcare Manufacturing Leaders Network